Clinical Trials Browser

INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Everolimus × Clear all

NCT00093639 2013-05-01

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase